Monte Rosa Therapeutics (GLUE) Retained Earnings (2020 - 2026)

Monte Rosa Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$521.7 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 15571.88% year-over-year to -$521.7 million; the TTM figure through Mar 2026 stood at -$521.7 million (down 15571.88% YoY), while the FY2025 annual figure was -$3.8 million, down 14.03% from the prior year.
• Retained Earnings was -$521.7 million for Q1 2026 at Monte Rosa Therapeutics, down from -$3.8 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$1.4 million in Q1 2023 to a low of -$521.7 million in Q1 2026.
• Historically, Retained Earnings has averaged -$190.3 million across 5 years, with a median of -$146.0 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings jumped 99.05% in 2023, then tumbled 15571.88% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$1.8 million in 2022, then tumbled by 55.48% to -$2.7 million in 2023, then decreased by 23.2% to -$3.4 million in 2024, then slipped by 14.03% to -$3.8 million in 2025, then slumped by 13532.53% to -$521.7 million in 2026.
• The last three Retained Earnings figures came in at -$521.7 million (Q1 2026), -$3.8 million (Q4 2025), and -$431.1 million (Q3 2025), per Business Quant data.